SOL [ReneSola] 6-K: (Original Filing)

[ReneSola Ltd Announces Fourth Quarter and Full Year 2014 Results JIASHAN, China, March 4, 2015 Fourth Quarter 2014 Financial and Operating Highlights · Total solar module shipments were 488.4 megawatts (“MW”), exceeding previous guidance and representing an increase of 5.7% from Q3 2014. Total solar wafer and module shipments in Q4 2014 were 744.3 MW, representing an increase of 12.1%] []

By | 2016-03-19T05:09:30+00:00 March 4th, 2015|Categories: Chinese Stocks, SEC Original, SOL|Tags: , , , , , |0 Comments

SOL [ReneSola] 6-K: ReneSola Ltd Announces Fourth Quarter and Full Year

[ReneSola Ltd Announces Fourth Quarter and Full Year 2014 Results JIASHAN, China, March 4, 2015 Fourth Quarter 2014 Financial and Operating Highlights · Total solar module shipments were 488.4 megawatts (“MW”), exceeding previous guidance and representing an increase of 5.7% from Q3 2014. Total solar wafer and module shipments in Q4 2014 were 744.3 MW, representing an increase of 12.1%] []

By | 2016-03-19T05:11:39+00:00 March 4th, 2015|Categories: Chinese Stocks, SOL, Webplus ver|Tags: , , , , , |0 Comments

KANG [iKang Healthcare] 6-K: (Original Filing)

[Press Release iKang Announces Two Acquisitions in Tianjin to Continue Its Nationwide Network Expansion BEIJING, March 3, 2015 (GLOBE NEWSWIRE) — iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq:KANG), today announced that it had completed the acquisitions of Tianjin Hexi Kangmeng Hezhong Clinic Co., Ltd. and Tianjin Hedong District REMAHO Clinic Co., Ltd., which were set up in 2008] [FORM 6-K IKANG HEALTHCARE GROUP, INC. B-6F, Shimao Tower 92A Jianguo Road Chaoyang District, Beijing 100022 People’s Republic of China Form 20-F x Form 40-F o o o IKANG HEALTHCARE GROUP, INC.]

KANG [iKang Healthcare] 6-K: Press Release iKang Announces Two Acquisitions in Tianjin

[Press Release iKang Announces Two Acquisitions in Tianjin to Continue Its Nationwide Network Expansion BEIJING, March 3, 2015 (GLOBE NEWSWIRE) — iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq:KANG), today announced that it had completed the acquisitions of Tianjin Hexi Kangmeng Hezhong Clinic Co., Ltd. and Tianjin Hedong District REMAHO Clinic Co., Ltd., which were set up in 2008] [FORM 6-K IKANG HEALTHCARE GROUP, INC. B-6F, Shimao Tower 92A Jianguo Road Chaoyang District, Beijing 100022 People’s Republic of China Form 20-F x Form 40-F o o o IKANG HEALTHCARE GROUP, INC.]

CBPO [China Biologic Products] 8-K: (Original Filing)

[CHINA BIOLOGIC PRODUCTS, INC. DIRECTOR AGREEMENT Agreement Company Mr. Min Fang Director THIS AGREEMENT (The “ BACKGROUND The Board of Directors of the Company desires to appoint the Director to fill an existing vacancy due to resignation of Mr. Dai Feng and to have the Director perform the duties of a director and the Director desires to be so appointed] [FOR RELEASE March 4, 2015 China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 4Q14 Total Sales Up 36.2% to 58.0 Million / FY14 Total Sales Up 19.6% to $243.3 Million -- -- -- 4Q14 Operating Margin Up 470 Basis Points to 34.0% / FY14 Operating Margin Up 300 Basis Points to 45.7% -- -- 4Q14] []

CBPO [China Biologic Products] 8-K: CHINA BIOLOGIC PRODUCTS, INC. DIRECTOR AGREEMENT Agreement Company

[CHINA BIOLOGIC PRODUCTS, INC. DIRECTOR AGREEMENT Agreement Company Mr. Min Fang Director THIS AGREEMENT (The “ BACKGROUND The Board of Directors of the Company desires to appoint the Director to fill an existing vacancy due to resignation of Mr. Dai Feng and to have the Director perform the duties of a director and the Director desires to be so appointed] [FOR RELEASE March 4, 2015 China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 4Q14 Total Sales Up 36.2% to 58.0 Million / FY14 Total Sales Up 19.6% to $243.3 Million -- -- -- 4Q14 Operating Margin Up 470 Basis Points to 34.0% / FY14 Operating Margin Up 300 Basis Points to 45.7% -- -- 4Q14] []

CBPO [China Biologic Products] 10-K: (Original Filing)

[Annual Report on Form 10-K Year Ended December 31, 2014 TABLE OF CONTENTS PART I Item 1. Business 3 Item 1A. Risk Factors 22 Item 1B. Unresolved Staff Comments 44 Item 2. Properties 44 Item 3. Legal Proceedings 45 Item 4. Mine Safety Disclosures 47 PART II Item 5. 48 Item 6. Selected Financial Data 49 Item 7. Management’s Discussion] [23.1 Consent of Independent Registered Public Accounting Firm The Board of Directors China Biologic Products, Inc.: We consent to the incorporation by reference in registration statements (No. 333-171069, 333-182624 and 333-196591) on Form S-3 and the registration statement (No. 333-151263) on Form S-8 of China Biologic Products, Inc. of our reports dated March 4, 2015, with respect to the consolidated] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang Chief Financial Officer (Principal Financial and Accounting Officer)]

HSOL [Hanwha Q CELLS] 6-K: (Original Filing)

[HANWHA Q CELLS APPOINTS TWO SENIOR EXECUTIVES AS DIRECTORS DK KIM RETURNS TO BOARD Company Hanwha Q CELLS SEOUL, SOUTH KOREA — March 4, 2015 — Hanwha Q CELLS Co., Ltd. (the “ Mr. Seongwoo Nam, chairman and chief executive officer of Hanwha Q CELLS, said, “Both Mr. Kim and Dr. Choi bring unique skills to our Board. Mr. Kim] [Hanwha Q CELLS Co., Ltd. Seong Woo Nam Chairman and CEO 6-K 1 d884271d6k.htm FORM 6-K]

By | 2016-04-03T00:51:16+00:00 March 4th, 2015|Categories: Chinese Stocks, HSOL, SEC Original|Tags: , , , , , |0 Comments
Skip to toolbar